Back to Top Skip to main content
Alert Arrow ALERT!!

There are emergency procedures in place for parts of world due to weather.

Get the latest information on emergency prescription refills and PCM referral waivers. 

DoD P&T Committee Resources

View and download Formulary Management Documents and/or Executive Summaries from below.

Formulary Management Documents

File Date
Formulary Management for the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) 5/21/2018
Formulary Management of Weight Loss Agents 5/21/2018
Formulary Management for Basal Insulin Analogs 11/2/2017
Formulary Management for Ophthalmic-1s: Antihistamine and Dual Acting Antihistamine/Mast Cell Stabilizers 8/18/2017
Formulary Management for Idiopathic Pulmonary Fibrosis 8/18/2017
Formulary Management for Diabetes Drugs 3/20/2017
Formulary Management for Oral Anticoagulants 2/21/2017
Formulary Management for PCSK9 Inhibitors 2/21/2017
Formulary Management for Narcotic Antagonists August 2016 11/28/2016
Formulary Management for Topical Acne and Rosacea Agents August 2016 11/28/2016
Formulary Management for Triptans August 2016 11/28/2016
Formulary Management for Anticonvulsants and Anti Mania Agents 8/2/2016
Formulary Management for Atypical Antipsychotic Agents 8/2/2016
Formulary Management for Emergency Contraceptive Agents 8/2/2016
Formulary Management for Opthalmic Immunomodulatory Agents: Cyclosporine 0.05% Opthalmic Emulsion 5/19/2016
Formulary Management for Oral Contraceptives and Miscellaneous Contraceptives 5/19/2016
Formulary Management for OTC Doxylamine 5/19/2016
Formulary Management for Topical Antifungals for Onychomycosis Subclass 5/19/2016
Formulary Management Table for Oral Contraceptives 5/19/2016
Formulary Management for Gastrointestinal-2 (GI-2) Miscellaneous Drugs 2/17/2016
Formulary Management for Anti-Rheumatic Drugs; Injectable Methtrexate Subclass 2/16/2016
Formulary Management for Attention Deficit/Hyperactivity Disorder Stimulant Agents 2/16/2016
Formulary Management for Oral Isotretinoins for Severe Recalcitrant Nodular Acne 2/16/2016
Formulary Management for Chronic Myelogenous Leukemia 12/14/2015
Formulary Management for Long Acting High Potency Narcotic Analgesics 12/14/2015
Formulary Management for Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2) 12/14/2015
Formulary Management for Hepatitis C Virus Direct Acting Agents 9/2/2015
Formulary Management for Self-Monitoring Blood Glucose Systems (SMBGS) Test Strips 9/2/2015
Formulary Management for Nitric Oxide Agents Used in the Treatment of Pulmonary Arterial Hypertension 7/1/2015
Formulary Management for Prostate Subclass I and II Cancer Drugs 7/1/2015
Formulary Management for Transmucosal Immediate Release Fentanyl Products 7/1/2015
Formulary Management for Multiple Sclerosis Drugs 2/1/2015
Formulary Management for Targeted Immunomodulatory Biologics 12/1/2014
Formulary Management for Inhaled Corticosteroids 9/1/2014
Formulary Management for Inhaled Nasal Allergy Drugs 9/1/2014
Formulary Management for Oral Bisphosphonates 9/1/2014
Formulary Management for Gastrointestinal-1 Drug Class Oral Aminosalixylates (5-ASA) Subclass 7/1/2014
Formulary Management for Inhaled Corticosteroids/Long-Acting Beta Agonists (ICS/LABAs) 7/1/2014

Executive Summaries

File Date
DoD P&T Committee Executive Summary: Ophthalmic-1s: Antihistamine and Dual Acting Antihistamine/Mast Cell Stabilizers 8/22/2017
DoD P&T Committee Executive Summary: Idiopathic Pulmonary Fibrosis 8/22/2017
DoD P&T Committee Executive Summary: Direct-Acting Anticoagulants 5/11/2017
DoD P&T Committee Executive Summary: PCSK9 Inhibitor Subclass 2/21/2017
DoD P&T Committee Executive Summary: Migraine Agents - Triptans 11/28/2016
DoD P&T Committee Executive Summary: Alcohol Deterrents - Narcotic Antagonist 11/28/2016
DoD P&T Committee Executive Summary: Topical Acne and Rosacea Agents 11/28/2016
DoD P&T Committee Executive Summary: Anticonvulsants and Anti Mania Agents 8/1/2016
DoD P&T Committee Executive Summary: Atypical Antipsychotic Agents 8/1/2016
DoD P&T Committee Executive Summary: Emergency Contraceptive Agents 8/1/2016
DoD P&T Committee Executive Summary: Contraceptive Agents 5/19/2016
DoD P&T Committee Executive Summary: Ophthalmic Immunomodulatory Agents Cyclosporine 0.05% Ophthalmic Emulsion (Restasis) 5/19/2016
DoD P&T Committee Executive Summary: Topical Antifungal Drugs for Onychomycosis 5/19/2016
DoD P&T Committee Executive Summary: Chronic Myelogenous Leukemia 12/14/2015
DoD P&T Committee Executive Summary: Extended Release Opioids 12/14/2015
DoD P&T Committee Executive Summary: Glucagon-Like Peptide-1 Receptors Agonist (GLP1RA) 12/14/2015
DoD P&T Committee Executive Summary: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2) 12/14/2015
DoD P&T Committee Executive Summary: Hepatitis C Virus Direct Acting Agents 5/1/2015
DoD P&T Committee Executive Summary: Pulmonary Arterial Hypertension Drugs 2/1/2015
DoD P&T Committee Executive Summary: Prostate Cancer Subclass I/II Drugs Oral Oncology 2/1/2015
DoD P&T Committee Executive Summary: Transmucosal Immediate Release Fentanyl Products 2/1/2015

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.